SELLAS Life Sciences plunge nearly 37% after pricing its public offering of 4.63M shares and warrants at $5.40 per share, according to a news release by SELLAS on Thursday.

  • SELLAS Life Sciences Group, Inc is a late-stage clinical biopharmaceutical company that focuses on the development of novel therapies for a wide range of cancer indications.
  • The warrants to purchase shares of common stock are immediately exercisable and are set to expire five years from the date of issuance.
  • All stocks in the public offering will be sold by SELLAS, with total proceeds to SELLAS anticipated to be $25 million before deducting underwriting discounts, commissions, and offering expenditures. 

The public offering is set to be finalized on April 5, 2022, after complying with customary closing requirements. SLS: NASDAQ is down -36.53%, Pre-market trading